Using Avapritinib for treating specific types of gastrointestinal stromal tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of Avapritinib in patients with unresectable or recurrent metastatic gastrointestinal stromal tumors (GIST) that have non-exon18 mutations of the PDGFRA gene. It involves multiple centers and focuses on real-world outcomes for patients who have been treated with Avapritinib. The study will assess tumor response and patient survival, providing insights into the drug's impact on this specific patient population. Participants will be monitored for their treatment progress and any associated side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who are aged ≥ 18 years.
* Gastrointestinal stromal tumors confirmed by histopathological examination, and CD- and/or DOG-1-positive by immunohistochemistry.
* Presence of mRECIST v1.1-compliant lesions with at least one measurable lesion (non-lymphadenopathy ≥1.0 cm or ≥2-fold scan slice thickness).
* Treatment with Avapritinib.
* Patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2 at screening.
* Patient informed consent and signed written consent form.
* The patient was compliant and voluntarily scheduled for follow-up, treatment, laboratory tests, and other study procedures.

Exclusion Criteria:

* KIT or PDGFRA wild type.
* Failure to complete continuous atorvastatin for at least 15 days due to intolerability or disease progression.
* Other serious acute or chronic physical or mental problems, or laboratory abnormalities, may increase the risk associated with participation in the study or use of drugs, or interfere with the judgment of the study results and, in the judgment of the investigator, are not considered appropriate for participation in the investigator.

Where it's running

• The First Affiliated Hospital, Sun Yat-sen University
  Guangzhou, China Recruiting

Study contacts

• Principal investigator: Xinhua Zhang, PhD — First affiliated hosptial,Sun Yat-sen university
• Study coordinator: Xinhua Zhang, PhD
• Email: zhangxinhua@mail.sysu.edu.cn
• Phone: +8620-87332200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating Avapritinib for Advanced Gastrointestinal Stromal Tumors

  This study is testing if Avapritinib can help people with advanced gastrointestinal stromal tumors feel better and improve their health in real-world situations.

  Recruiting First Affiliated Hospital, Sun Yat-Sen University · Guangzhou · NCT05464875

• Adding targeted GRID-style radiation to standard palliative therapy for unresectable solid tumors

  This study tests whether adding spatially fractionated radiation therapy to standard palliative radiation helps relieve symptoms in patients with unresectable solid tumors.

  Recruiting at 2 sites Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT07856394

• DS1025a: first-in-human test in advanced solid tumors

  This first-in-human trial tests DS1025a in adults with advanced, metastatic, or unresectable solid tumors to see if it is safe and tolerable and to look for early signs of activity.

  Recruiting at 3 sites Phase 1 Daiichi Sankyo · Kashiwa and 2 other locations · NCT07681882

• MSK-TCR5 in adults with advanced solid tumors that have KRAS/HRAS/NRAS G12D

  This study tests MSK-TCR5 to see if it is safe for adults with advanced solid tumors carrying a KRAS, HRAS, or NRAS G12D mutation.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07638371

• DCC-2618 in GIST after at least 3 prior treatments

  This trial tests whether DCC-2618 is safe in people with advanced GIST who have already tried at least three other treatments.

  Recruiting at 2 sites Phase 1 Ono Pharmaceutical Co., Ltd. · Kashiwa, Chiba and 1 other locations · NCT07618377

• RGT-490 for adults with PIK3CA-mutated advanced solid tumors

  This trial will test RGT-490, an oral medicine, in adults whose advanced solid tumors carry a PIK3CA mutation and have progressed after prior therapy.

  Recruiting at 6 sites Phase 1 Regor Pharmaceuticals Inc. · Los Angeles, California and 5 other locations · NCT07524322

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.